****

**Systematic Review**

**Education on Inhaler Technique by Pharmacists To Improve The Quality of Life of COPD Patients.: A Systematic Review**

|  |  |
| --- | --- |
| **Abstract** **Background:** This systematic review aimed to analyze the importance of education on using inhalers by pharmacists in improving quality of life, correct inhaler use steps, and medication adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).**Methods:** The databases used to search for articles in this systematic review include Scopus, ScienceDirect, and Pubmed. The articles submitted were published between 2009 and 2022, with the most recent search being conducted in December 2022. This review included a randomized controlled trial evaluating education on inhaler use techniques by pharmacists in improving the quality of life of COPD patients in inpatient and outpatient settings. This systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) writing guidelines.**Results:** This systematic review used six articles from five different countries. The articles involved share similar characteristics so that analysis can be carried out. The total number of research subjects included was 913 subjects. Most studies show that there is an increase in the quality of life among COPD patients who are given education on how to use inhalers by pharmacists using print or digital media. Measurements using the St. George's Respiratory Questionnaire (SGRQ) showed a decrease in scores at the 6-month and 12-month periods (-0.75 [95% CI (-1.46 - (-.005)]. Furthermore, two articles reported that education on the technique of using inhalers by pharmacists can also increase the accuracy of using inhalers and three articles reported increasing medication adherence. **Conclusion:** Interventions such as education on the technique of using inhalers by pharmacists in inpatient and outpatient settings can improve the quality of life of COPD patients, the accuracy of the steps in using inhalers, and medication adherence.**Keywords:** Inhaler Technique Education, COPD, Hospital Pharmacist  |  |

**INTRODUCTION**

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms (shortness of breath, coughing, sputum production), caused by abnormalities of the respiratory tract (bronchitis/bronchiolitis) and/or alveoli (emphysema), resulting in persistent, progressive, and airway obstruction[1](#GOLD2023). COPD is a leading cause of death and disability worldwide. According to The Global Burden of Disease Study 2019, COPD is the sixth leading cause of death, up from 11th in the previous ranking[2](#GBD2019). COPD prevalence reached 212.3 million in 2019, with 3.3 million deaths and 74.4 disability-adjusted life years (DALYs)[3](#Safiri_S). The rise in COPD cases worldwide can be attributed to a variety of risk factors, including smoking status, cigarette smoke exposure, occupational exposure to particulates, gases, and smoke, household air pollution from solid fuels, ambient ozone pollution, and low and high temperatures[4](#Zou_J). COPD prevalence is expected to rise in the coming years, and the World Health Organization predicts that COPD will be the third leading cause of death in the world by 2030[5](#Wang_C),[6](#WHO_EMRO). Based on this, effective COPD management in the form of lifestyle changes and long-term commitment to treatment in patients who are already receiving treatment is required to prevent increased morbidity[5](#Wang_C),[7](#Bhattarai_B).

 According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the main treatment recommended to improve symptoms in COPD is inhalation therapy. Several studies have found that poor adherence to inhaler use is caused by inappropriate use of inhalers and poor inhalation techniques. Non-compliance with inhalation therapy results in decreased lung function, more exacerbations, and an increased risk of hospitalization[8](#Monteiro)[9](#GOLD_2022). According to one study, data on non-adherence to therapy in COPD patients reached 79.4% of a total of 504 patients and only 6.3% of 765 patients can use inhalers properly[10](#Galal_IH) [11](#Sanaullah_T). Therefore, education in inhaler use plays a vital role in managing COPD patients. It should be emphasized that patient education about inhaler use is carried out when prescribing inhaler devices, and it is recommended that inhaler use be assessed at each visit. Repeated education and assessments are required to regularly maintain proper inhalation technique and patient compliance.[9](#GOLD_2022) [12](#Lindh_A)

 There was only one systematic review with a randomized controlled trial study that reported that the pharmacist's role in the hospital has contributed to various aspects of COPD management, both inpatient and outpatient[13](#Lin_G). Therefore, this systematic review aimed to evaluate specifically the impact of providing education on the technique of using inhalers by hospital pharmacists in improving the quality of life of inpatient and outpatient COPD patients. The purpose of selecting inpatients and outpatients is to assist patients to improve treatment safety, patient outcomes, drug quality over time, and to prevent readmissions in inpatient settings[14](#Press_VG) [15](#Snosswell_CL)

**METHODS**

1. **Search Strategy**

Search databases such as Pubmed, ScienceDirect, and Scopus were used to perform a literature search. The articles involved in this search were those published in 2009-2022, with the last search taking place in December 2022 The combination of keywords used in the search in this article were Pharmacy, COPD, Inhaler, Hospital, Outpatient, Quality of life, with more information available in Supplementary Table 1.

1. **Inclusion and Exclusion Criteria**

The inclusion criteria used in this review were the PICO criteria as follows:

* Participation / Population

COPD inpatients and outpatients

* Intervention / Exposure

Pharmacists provide verbal or face-to-face instruction on the proper use of inhalers, supplemented by leaflets, videos, and other media.

* Comparator / Control

Education on inhaler use techniques by pharmacists only verbal or face-to-face.

* Outcome

The primary outcome is an assessment of the quality of life of COPD patients assessed using the COPD Assessment Test (CAT), St. George Respiratory Question (SGRQ), and Other Instrument of Quality of Life. The secondary outcomes in this systematic review are correct inhaler technique and medication adherence.

The exclusion criteria set in this review were non-English speaking articles, non-open access articles, non-original research articles, and non-randomized controlled trial (RCT) articles.

1. **Data Extraction**

All research articles were extracted by two reviewers (SA and VP) using Microsoft Excel and Mendeley. Differences in data extraction were resolved by the third reviewer (RS). The reviewers screened the articles that met the inclusion and exclusion criteria set by agreement with a kappa value of 0.86 (listed in Supplementary Table 2). The data extraction process was then depicted in the flowchart of The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), as listed in Figure 1. Details of data extraction are listed in Supplementary Table 3.

Included

Identification

Screening

Studies Identified from (n = 428 ):

* **ScienceDirect (n = 66)**
* **PubMed (n= 49)**
* **Scopus (n= 313)**

Studies removed before screening

* Duplicates (n = 30)

Studies Screened (n = 398 )

Studies excluded based on titles and abstracts (n = 382)

Studies assessed for eligibility

(n = 16)

Articles included in Sytematic Review (n = 6)

Identification of Studies via Databases and Registers

Identification of Studies via Other methods

Records Identified from

* Handsearching (n = 3)

Studies sought for retrieval (n= 3)

Studies assessed for eligibility (n= 3)

Studies excluded (n = 13)

* Single Arm (n = 8)
* not *inpatient* or *outpatient* (n = 4)
* Education not using media (n = 1)

Articles included in Quantative synthesis (n = 3)

**Figure 1**. PRISMA Flowchart

1. **Quality Assessment and Risk of Bias**

To reduce the risk of bias, the stages of article screening are carried out by two independent reviewers using The Medical Education Research Study Quality Instrument (MERSQI) Score[16](#Cook_DA). The Medical Education Research Study Quality Instrument (MERSQI) can be used to assess the quality of experimental studies. It consists of ten items with 6 domains of study quality. The domain of study quality encompasses study design, sampling, data type (subjective or objective), validity, data analysis, and results. The maximum score for each domain is 3, with a maximum score of 18, and the possible scores range from 5 to 18[17](#Reed_DA).

1. **Data Synthesis and Analysis**

The studies included in this review were summarized using the narrative description method. The results of this review were focused on improving the quality of life in COPD patients who receive education on using inhalers via media such as leaflets or videos. The quality of life assessment instruments used were the St-George Respiratory Questionnaire (SGRQ) and the COPD Assessment Test (CAT). In the CAT and SGRQ assessment instruments, COPD patients are said to have a good quality of life if their CAT and SGRQ scores are low, with a maximum CAT score limit of 40 points and an SGRQ score limit of 100 points.

We analysed the RCT data using Review Manager 5.4 (RevMan 5.4.1), which was made available by the Cochrane. Analyzed data consists of continuous data measured using Standardized Mean Difference (SMD). Standardized Mean Difference (SMD) was utilized because the included studies collected data at different scales or units. Subsequently, using the random-effects method, observe the effect. Quantitative evaluation of heterogeneity using Cochrane I2 statistics. A random effects model is applied if I2 is greater than 50 percent, indicating statistically significant heterogeneity; otherwise, the effects model is maintained. We performed subgroup analysis in high heterogeneity (I2 > 50 %) to identify good heterogeneity causes.

**RESULTS**

1. **Article Research Results**

Based on article searches through database searches, a total of 428 articles were obtained and three were obtained through other search methods. The search for these articles yielded six articles that met the PICO criteria established in this review. The articles included in this study had good agreement reached by three reviewers (SA, VP, RS) with a kappa value of 0.86. The flowchart of the article search is presented in Figure 1.

1. **Study Quality**

The study quality was examined using The Medical Education Research Study Quality Instrument (MERSQI) Score and is presented in Table 1. Based on the assessment of study quality using the MERSQI score, six studies included in this review received an average score of 14. This score falls within the MERSQI's potential range of 5-18. [17](#Reed_DA)

**Table 1.** Results of The MERSQI Score

| **Domain** | **MERSQI Item** | **Score** | **Max Score** | **Wang, et al. 2020** | **Suhaj, et al. 2015** | **Xin, et al. 2016** | **Khdour, et al. 2009** | **Jarah, et al. 2011** | **Kebede AT, et al. 2022** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study Design | Single group cross-sectional or single group post-test only | 1 | 3 |   |   |   |   |   |   |
| Single group pre test & post test | 1,5 |   |   |   |   |   |   |
| Non Randomized, 2 groups | 2 |   |   |   |   |   |   |
| Randomized Controlled Trial | 3 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Sampling | Institutions studied : |  | 3 |   |   |   |   |   |   |
| 1 | 0,5 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 2 | 1 |   |   |   |   |   |   |
| 3 | 1,5 |   |   |   |   |   |   |
| Respons rate, % |  |   |   |   |   |   |   |
| Not applicable |  |   |   |   |   |   |   |
| <50 or not reported | 0,5 |   |   |   |   |   |   |
| 50-74 | 1 |   |   |   |   |   |   |
| ≥75 | 1,5 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Type of Data | Assessment by participants | 1 | 3 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Objective measurement | 3 |   |   |   |   |   |   |
| Validity of Evaluation Instrument | **Internal structure** |  | 3 |   |   |   |   |   |   |
| - Not applicable |  |   |   |   |   |   |   |
| - Not reported | 0 |   |   |   |   |   |   |
| - Reported | 1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| **Content** |  |   |   |   |   |   |   |
| - Not applicable |  |   |   |   |   |   |   |
| - Not reported | 0 |   |   |   |   |   |   |
| - Reported | 1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| **Relationshipes to other variables** |  |   |   |   |   |   |   |
| - Not applicable |  |   |   |   |   |   |   |
| - Not reported | 0 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| - Reported | 1 |   |   |   |   |   |   |
| Data Analysis | Approriateness of analysis |  | 3 |   |   |   |   |   |   |
| - Inapproriate for study design or type of data | 0 |   |   |   |   |   |   |
| - Approriate for study design or type of data | 1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Complexity of analysis |  |   |   |   |   |   |   |
| - Descriptive analysis only | 1 |   |   |   |   |   |   |
| - Beyond Descriptive analysis | 2 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Outcome | Satisfaction, attitudes, perceptions, opinions, general facts | 1 | 3 |   |   |   |   |   |   |
| Konowledge, skills | 1,5 |   |   |   |   |   |   |
| Behaviors | 2 |   |   |   |   |   |   |
| Patient/health care outcome | 3 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| **Total Possible score** |   |   | 18 | 14 | 14 | 14 | 14 | 14 | 14 |

1. **Study Characteristics**

The studies listed in this review were conducted in a variety of countries, including India, Ireland, Jordan, Norway, and China. All of the studies used a randomized study design with two groups. All subjects in the study had been diagnosed with COPD using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and were over 45 years old. The COPD Assessment Test (CAT) and St. George's Respiratory Questionnaire (SGRQ) were used in all studies to assess COPD patients' quality of life. Data on study characteristics are listed in Supplementary Table 3.

Table 2 displays data from the articles used in this review on the characteristics of COPD patients. According to the table, several articles are missing economic conditions, education level, type/level of work, and smoking status.

**Table 2.** Characteristics of COPD Patients

|  |  |  |  |
| --- | --- | --- | --- |
| **Authors** | **Location** | **Setting** | **COPD risk factors (excluding age)**  |
| **Education (%)** | **Type/Level of Work (%)** | **Economic Conditions (%)** | **Smoking Status (%)** |
| Khdour, et al. 200918 | Northern Ireland | *Outpatient* | Moderate (71,70) | Lower (63,55) | n/a | Ex-Smokers (65,30) |
| Jarab, et al. 2012 19 | Jordan | *Outpatient* | Lower (90,20) | Lower (60,15) | n/a | Current Smokers (56,55) |
| Suhaj, et al. 201520 | India | *Outpatient* | n/a | n/a | Lower (36,6) | Current Smokers (55,35) |
| Xin, et al. 201621 | China | *Outpatient* | Lower (70,45) | n/a | n/a | Current Smokers (74,40) |
| Wang, et al. 202022 | China | *Outpatient* | Lower (47) | n/a | n/a | n/a |
| Kebede, et al. 202223 | Norway | *Inpatient* | n/a | n/a | n/a | n/a |

**Table 3.** The Outcome of Quality of Life Using St. George Respiratory Questionnaire (SGRQ)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Authors** | **Type of Intervention** | **Time** | **Control Group\*** | **Intervention Group\*** | ***p*-value** |
| Khdour, et al. 200918 | Booklet regarding the use of inhalers and COPD management | Baseline | 64.20 | 63.60 | 0.690 |
| 6 months | 64.20 | 59.20 | 0.040 |
| 12 months | 65.30 | 61.80 | 0.170 |
| Jarab, et al. 201219 | Booklets regarding the use of inhalers and knowledge about COPD | Baseline | 44.80 | 45.20 | 0.760 |
| 6 months | 42.70 | 42.30 | 0.510 |
| Suhaj, et al. 201520 | Patient Information Leaflets (PILs) | Baseline | 50.60 | 50.90 | 0.949 |
| 6 months | 49.20 | 47.20 | 0.618 |
| 12 months | 52.40 | 42.70 | 0.024 |
| Xin, et al. 201621 | Inhaler use educational leafletFace to face COPD related education | Baseline | 68.40 | 68.50 | 0.913 |
| 6 months | 68.30 | 61.70 | 0.001 |
| 12 months | 67.80 | 61.62 | 0.001 |
| 18 months | 68.50 | 61.31 | 0.001 |
| 24 months | 68.50 | 60.40 | 0.001 |

\*SGRQ Total Score

**Table 4.** The Outcome of Quality of Life Using COPD Assessment Test (CAT)

|  |  |  |  |
| --- | --- | --- | --- |
| **Authors** | **Type of Intervention** | **Control Group**\* | **Intervention Group**\* |
| **Pre** | **Post** | ***p*-value** | **Pre** | **Post** | ***p*-value** |
| Wang, et al. 202022 | Brochures regarding COPD and how to use inhalersVideo of inhaler use is sent to the patient's cell phone | 19.39 | 18.44 | 0.461 | 19.81 | 15.67 | 0.021 |
| Kebede, et al. 202223 | Information sheet regarding inhalers, such as effects (reliever/controller), onset, side effects that often arise, and techniques for using inhalers | 24.00 | 24.00 | >0.05 | 29.00 | 25.50 | 0.290 |

\*CAT Total Score



**Figure 2.** Forest Plot of Quality of Life (SGRQ)



**Figure 3.** Funnel Plot of Quality of Life by SGRQ instrument

1. **Quality of Life in COPD Patients**

Two studies measured the quality of life instrument with the CAT, and four studies with the SGRQ. Research conducted by Jarab, et al., Khdour et.al., Suhaj et.al., and Xin et.al showed an improvement in quality of life based on an assessment using the SGRQ instrument, although the increase in quality of life in the study conducted by Jarab et.al. was not significant. Other studies conducted by [Wang et.al, 2020](#Wang_W) and [Kebede, et.al, 2022](#Kebede_AT) reported that providing education on the use of inhalers using videos or information sheets can improve the quality of life in COPD patients as assessed by the CAT instrument. [Kebede et.al, 2022](#Kebede_AT) reported a decrease in the median CAT value of the intervention group between baseline and two months following discharge by 3.5 points. However, this result was not statistically significant when compared to the control group at 2 months after discharge (*p* > 0.05). Meanwhile, [Wang et.al, 2020](#Wang_W) reported a significant decrease in the average CAT score in the intervention group of 4.15 points (*p* < 0.05) compared to the control group which showed no significant differences between the pre-and post-intervention periods (*p* > 0.05).

A meta-analysis was conducted using the random effect depicted in Figure 2. The subgroup meta-analysis was conducted between different measurement instruments and assessment period. Due to the limited availability of studies analyzed using the CAT instrument, subgroup analysis was exclusively conducted utilizing the SGRQ instrument. According to the results of the analysis, administering the intervention can substantially reduce the SGRQ score during the 6th and 12th month assessment periods (-0.75 [95% CI (-1.46 - (-.005)]. The effect of subgroup analysis on I2 scores was insignificant (Figure 2).

1. **Inhaler Use Technique Accuracy**

In this systematic review, two studies reported data related to the inhaler use technique accuracy in COPD patients, with the full details shown in Table 5.

**Table 5**. Inhaler Use Technique Accuracy

|  |  |  |
| --- | --- | --- |
| Authors | *Control Group* (*p*-value)\* | *Intervention Group* (*p*-value)\* |
| Wang, et al. 2020[22](#Wang_W) | <0.01 | <0.01 |
| Kebede, et al. 2022[23](#Kebede_AT) | >0.05 | >0.05 |

\*Comparison of pre and post-intervention in each group

1. **Medication Adherence**

A total of three studies reported medication adherence data on COPD patients, which is presented in full in Table 6. There are 2 methods used to measure medication adherence, including the medication refill adherence method, which was used in one study, and the Morisky Scale method, which has been used in two studies[18](#Khdour_MR),[19](#Jarab_AS),[21](#Xin_C).

**Table 6.**Medication Adherence

|  |  |  |  |
| --- | --- | --- | --- |
| **Authors** | **Method of medication adherence** | **Baseline (*p-value*)** | ***Follow-up* (*p-value*)** |
| Khdour et al. 200918 | Morisky Scale | 0.840 | 0.019\* |
| Jarab et al, 201219 | Morisky Scale | 0.680 | 0.017\* |
| Xin et al. 201621 | Medication Refill Adherence | 0.798 | 0.003\* |

**DISCUSSION**

1. **Discussion**

Six articles met the criteria for inclusion and exclusion based on the systematic review's inclusion and exclusion rules. The studies included in this systematic review share similar results, even though they were conducted at six different locations. This is in accordance with data from The Global Burden of Disease Study 2019, which states that the risk factors for COPD include smoking, exposure to cigarette smoke, household air pollution from solid fuels, ambient particulate matter, ozone, and occupational particles[4](#GBD2019).

Four studies used the SGRQ instrument to measure the quality of life of COPD patients[18](#Khdour_MR)–[21](#Xin_C) and 2 studies used the CAT instrument to to evaluate COPD patients' quality of life[22](#Wang_W),[23](#Kebede_AT). Both of these instruments are recommended by GOLD in measuring the quality of life of COPD patients. Compared to the CAT, which only has 8 question items, the SGRQ instrument has 50 more complex question items. Although the question items from the two instruments differ, they both have a strong correlation (r = 0.73-0.80)[24](#Jones_PW),[25](#Ringbaek_T). One study using the CAT instrument showed a non-significant improvement in QoL at the 2-month follow-up period (*p* > 0.01)[23](#Kebede_AT). A total of 3 studies measuring the quality of life using the SGRQ instrument showed insignificant results at a specific follow-up period [18](#Khdour_MR),[19](#Jarab_AS),[21](#Xin_C). The occurrence of an insignificant improvement in quality of life could be caused by several factors, including small sample size, short follow-up duration, repeated education during the follow-up period, whether or not additional educational materials were provided in addition to inhaler use techniques, the level of education, and socioeconomic conditions[18](#Khdour_MR),[19](#Jarab_AS),[26](#Ying_Y),[27](#Acharya_Pandey).

In the original research reported in this systematic review, three articles reported outcomes in the form of medication *adherence*[18](#Khdour_MR),[19](#Jarab_AS),[21](#Xin_C). Medication Adherence is one of the key factors in suppressing COPD progression, which can also increase mortality and readmission28. Of the three articles, two of them used the Morisky Scale method while another one used medication refill adherence. These three studies showed that interventions provided by pharmacists could significantly increase adherence in COPD patients (p <0.05). This shows similar results to those of Nguyen TS et al. 2019[29](#Nguyen_TS) that interventions provided by pharmacists can increase adherence over time. Adherence in COPD patients can be influenced by three main factors including medication, unintentional, and intentional. Drug factors are those that are directly related to the drug, such as drug side effects and the ease of inhalers, as well as the correct inhalation technique, which can be difficult for patients to acquire, and other factors that are essential for achieving the optimal inhalation therapy[30](#DePietro_M). Intentional factors are non-adherence factors caused by patient intent, including patient perceptions that treatment is unnecessary, resistance to treatment, inappropriate expectations, focus on side effects, cultural or religious issues, and costs[31](#George_M). Unintentional factors include patient misperceptions of treatment that are unintentional, such as costs, forgetting to take medications, and misinterpreting inhaler usage instructions inhaler[31](#George_M).

In this systematic review, two studies reported outcomes in the form of the correct technique of using inhalers. A study conducted by [Wang et.al, 2020](#Wang_W) showed an improvement in the accuracy of using inhalers in the intervention group after monthly education was carried out during the follow-up period (p <0.01)22. Meanwhile, a study conducted by [Kebede et.al, 2022](#Kebede_AT) showed no significant difference between the control and intervention groups in terms of increasing the accuracy of the inhaler technique (p > 0.05)[23](#Kebede_AT). Based on the two articles, there is a finding that repeating education at each visit can improve patients' understanding of how to use inhalers correctly. The two articles provide the same results regarding the steps of inhaler use which often lead to inhaler misuse. The steps that often cause mistakes are standing straight before using the inhaler, breathing before using the inhaler, and holding breath after inhaling the inhaler. These errors affect effective drug inhalation and increase the risk of hospitalization or emergency room visits[32](#George_M).

The final results of our systematic review highlight the significance of hospital pharmacists in the administration of COPD treatment, with potential implications for medication adherence, inhaler accuracy, and COPD patients' quality of life. This systematic review updates the previous review by adding a 2022 RCT study. We compare the provision of education by pharmacists in inpatient and outpatient settings to improve quality of life, appropriateness of inhaler use, and treatment adherence in COPD patients. According to our most recent study, there was no discernible difference between both the control and the intervention groups regarding pharmacist education to reduce readmissions over the 12-month follow-up period (p=0,30).[23](#Kebede_AT). This is due to an imbalance in patient characteristics between the control and intervention groups. The intervention group had more study subjects who had readmissions in the last 1 year, a large number of inhalers used, high CAT scores, and many had comorbidities compared to the control group. Some patients had a comorbid disease and the cause of readmission was pneumonia (n=1), non-infectious exacerbation of asthma (n=1), pleural effusion (n=1), scheduled invasive test (n=4), congestive heart failure (n= 1), fall (n=1), erysipelas (n=1), chest pain (n=1), and atheroschlerosis (n=1).

**LIMITATION**

The limitations of this systematic review are the limited research on hospital pharmacists or clinical pharmacists regarding education on inhaler use and COPD management in outpatients and inpatients involving two research groups and pre-post intervention assessments. The advantage of this systematic review is that only prospective RCT-based articles are included for analysis.

**CONCLUSION**

Hospital pharmacists' education on inhaler use can enhance the accuracy of inhaler steps and medication adherence in COPD inpatients and outpatients. Therefore, the quality of life of COPD patients can be improved. Future studies should compare the results of RCTs on inhaler education with clinical outcomes, like testing the lung function of COPD patients in inpatient or outpatient settings.

**Acknowledgments**

**Conflict of Interest**

This review has no conflict of interest

**Funding**

None

**REFFERENCE**

1. GOLD. *GOLD 2023 Report*.; 2023. https://goldcopd.org/wp-content/uploads/2022/12/GOLD-2023-ver-1.1-2Dec2022\_WMV.pdf

2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9

3. Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. *BMJ*. Published online 2022. doi:10.1136/bmj-2021-069679

4. Zou J, Sun T, Song X, et al. Distributions and trends of the global burden of COPD attributable to risk factors by SDI, age, and sex from 1990 to 2019: a systematic analysis of GBD 2019 data. *Respir Res*. 2022; 23(1): 1-17. doi:10.1186/s12931-022-02011-y

5. Wang C, Liu K, Sun X, Yin Y, Tang T. Effectiveness of motivational interviewing among patients with COPD: A systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. *Patient Educ Couns*. 2022;105(11):3174-3185. doi:10.1016/j.pec.2022.07.019

6. who. WHO EMRO | Chronic obstructive pulmonary disease ( COPD ) | Health topics https://www.emro.who.int/health-topics/chronic-obstructive-pulmonary-disease-copd/index.html#:~:text=WHO predicts that COPD will , not always i …. Published 2023. Accessed February 5, 2023. https://www.emro.who.int/health-topics/chronic-obstructive-pulmonary-disease-copd/index.html#:~:text=WHO predicts that COPD will,not always implemented or accessible.

7. Bhattarai B, Walpola R, Khan S, Mey A. Factors associated with medication adherence among people living with COPD: Pharmacists’ perspectives. *Explor Res Clin Soc Pharm*. 2021;3:100049. doi:10.1016/j.rcsop.2021.100049

8. Monteiro C, Maricoto T, Prazeres F, Augusto Simões P, Augusto Simões J. Determining factors associated with inhaled therapy adherence on asthma and COPD: A systematic review and meta-analysis of the global literature. *Respir Med*. 2022;191(December 2021). doi:10.1016/j.rmed.2021.106724

9. GOLD. *Global Initiative for Chronic Obstructive Lung Disease (2022 Report)*. (Langefeld K, ed.). Global Initiative for Chronic Obstructive Lung Disease, Inc; 2021.

10. Galal IH, Mohammad YM, Nada AA, Mohran YE. Medication adherence and treatment satisfaction in some Egyptian patients with chronic obstructive pulmonary disease and bronchial asthma. *Egypt J Bronchol*. 2018;12(1):33. doi:10.4103/ejb.ejb

11. Sanaullah T, Khan S, Masoom A, Mandokhail ZK, Sadiqa A, Malik MI. Inhaler Use Technique in Chronic Obstructive Pulmonary Disease Patients: Errors, Practices and Barriers. *Cureus*. 2020;12(9):10-15. doi:10.7759/cureus.10569

12. Lindh A, Theander K, Arne M, et al. One additional educational session in inhaler use to patients with COPD in primary health care – A controlled clinical trial. *Patient Educ Couns*. 2022;105(May):2969-2975. doi:10.1016/j.pec.2022.05.013

13. Lin G, Zheng J, Tang PK, Zheng Y, Hu H, Ung COL. Effectiveness of Hospital Pharmacist Interventions for COPD Patients: A Systematic Literature Review and Logic Model. *Int J COPD*. 2022;17(October):2757-2788. doi:10.2147/COPD.S383914

14. Press VG, Arora VM, Shah LM, et al. Teaching the use of respiratory inhalers to hospitalized patients with asthma or COPD: A randomized trial. *J Gen Intern Med*. 2012;27(10):1317-1325. doi:10.1007/s11606-012-2090-9

15.  Snoswell CL, Draper MJ, Barras M. An evaluation of pharmacist activity in hospital outpatient clinics. *J Pharm Pract Res*. 2021;51(4):328-332. doi:10.1002/jppr.1729

16. Cook DA, Reed DA. Appraising the Quality of Medical Education Research Methods: The Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education. *Acad Med*. 2015;90(8):1067-1076. doi:10.1097/ACM.0000000000000786

17. Reed DA, Cook DA, Beckman TJ, Levine RB, Kern DE, Wright SM. Association between funding and quality of published medical education research. *Jama*. 2007;298(9):1002-1009. doi:10.1001/jama.298.9.1002

18. Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *Br J Clin Pharmacol*. 2009;68(4):588-598. doi:10.1111/j.1365-2125.2009.03493.x

19. Jarab AS, AlQudah SG, Khdour M, Shamssain M, Mukattash TL. Impact of pharmaceutical care on health outcomes in patients with COPD. *Int J Clin Pharm*. 2012;34(1):53-62. doi:10.1007/s11096-011-9585-z

20. Suhaj A, Manu MK, Unnikrishnan MK, Vijayanarayana K, Mallikarjuna Rao C. Effectiveness of clinical pharmacist intervention on health-related quality of life in chronic obstructive pulmonary disorder patients - A randomized controlled study. *J Clin Pharm Ther*. 2016;41(1):78-83. doi:10.1111/jcpt.12353

21. Xin C, Xia Z, Jiang C, Lin M, Li G. The impact of pharmacist-managed clinic on medication adherence and health-related quality of life in patients with COPD: A randomized controlled study. *Patient Prefer Adherence*. 2016;10:1197-1203. doi:10.2147/PPA.S110167

22. Wang W, Xu T, Qin Q, Miao L, Bao J, Chen R. Effect of a Multidimensional Pharmaceutical Care Intervention on Inhalation Technique in Patients with Asthma and COPD. *Can Respir J*. 2020;2020. doi:10.1155/2020/8572636

23. Kebede AT, Trapnes E, Lea M, Abrahamsen B, Mathiesen L. Effect of pharmacist-led inhaler technique assessment service on readmissions in hospitalized COPD patients: a randomized, controlled pilot study. *BMC Pulm Med*. 2022;22(1). doi:10.1186/s12890-022-02004-z

24. Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. *Eur Respir J*. 2011;38(1):29-35. doi:10.1183/09031936.00177210

25. Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. *COPD J Chronic Obstr Pulm Dis*. 2012;9(1):12-15. doi:10.3109/15412555.2011.630248

26. Ying Y. Factors associated with good quality of life among chronic objective pulmonary disease patients in Zhejiang province , China : a cross-sectional study. Published online 2022:1-26.

27. Acharya Pandey R, Chalise HN, Shrestha A, Ranjit A. Quality of life of patients with chronic obstructive pulmonary disease attending a tertiary care hospital, Kavre, Nepal. *Kathmandu Univ Med J*. 2021;19(74):180-185.

28. Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: Myth and reality. *Respir Med*. 2017;129:117-123. doi:10.1016/j.rmed.2017.06.007

29. Nguyen TS, Nguyen TLH, Pham TT Van, Hua S, Ngo QC, Li SC. Impact of pharmaceutical care in the improvement of medication adherence and quality of life for COPD patients in Vietnam. *Respir Med*. 2019;153(May):31-37. doi:10.1016/j.rmed.2019.05.006

30. DePietro M, Gilbert I, Millette LA, Riebe M. Inhalation device options for the management of chronic obstructive pulmonary disease. *Postgrad Med*. 2018;130(1):83-97. doi:10.1080/00325481.2018.1399042

31. GINA committee. Global Strategy for Asthma Management and Prevention 2022 Update. *Glob Initiat Asthma*. Published online 2022:225. http://www.ginasthma.org

32. George M, Bender B. New insights to improve treatment adherence in asthma and COPD. *Patient Prefer Adherence*. 2019;13:1325-1334. doi:10.2147/PPA.S209532